| 证券代码：603368 | 证券简称：柳药集团 公告编号：2025-077 | | --- | --- | | 转债代码：113563 | 转债简称：柳药转债 | 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，在回购期间，回购股份占上市公司总股本的比例 每增加 1%的，应当在事实发生之日起 3 个交易日内予以披露。现将公司回购股份 的进展情况公告如下： 广西柳药集团股份有限公司 关于以集中竞价交易方式回购股份比例达到 2%暨 回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/7/26 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 2025 7 25 7 | 日~2026 | 年 | 月 | 日 24 | | 预计回购金额 | 10,000万元~20,000万元 | | | | | | 回购用途 | ...

广西柳药集团股份有限公司 2025 年股票期权激励计划激励对象名单 | 16 | 李宏文 | 核心骨干 | 66 | 周健波 | 核心骨干 | | --- | --- | --- | --- | --- | --- | | 17 | 周德荣 | 核心骨干 | 67 | 阳晓菁 | 核心骨干 | | 18 | 谢勇 | 核心骨干 | 68 | 唐桂秀 | 核心骨干 | | 19 | 黄鸿海 | 核心骨干 | 69 | 李霜 | 核心骨干 | | 20 | 谢玉平 | 核心骨干 | 70 | 魏建强 | 核心骨干 | | 21 | 陈玉燕 | 核心骨干 | 71 | 胡龙英 | 核心骨干 | | 22 | 唐锦锋 | 核心骨干 | 72 | 陈飞丽 | 核心骨干 | | 23 | 鲁定琼 | 核心骨干 | 73 | 李玉生 | 核心骨干 | | 24 | 潘俞朴 | 核心骨干 | 74 | 韦盼钰 | 核心骨干 | | 25 | 卢福杏 | 核心骨干 | 75 | 宋宇 | 核心骨干 | | 26 | 高鹏 | 核心骨干 | 76 | 吴晓彤 | 核心骨干 | | 27 | 蒋仕军 | 核心骨干 | 77 | 彭 ...

| 证券代码：603368 | 证券简称：柳药集团 公告编号：2025-076 | | --- | --- | | 转债代码：113563 | 转债简称：柳药转债 | 广西柳药集团股份有限公司 关于召开2025年第二次临时股东会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 广西柳药集团股份有限公司（以下简称"公司"）于 2025 年 8 月 28 日召开第 五届董事会第二十八次会议，审议通过了《关于提请召开 2025 年第二次临时股东会 的议案》，并于 2025 年 8 月 29 日在上海证券交易所网站（www.sse.com.cn）及指定 媒体上披露了《关于召开 2025 年第二次临时股东会的通知》（公告编号：2025-072）， 本次股东大会定于 2025 年 9 月 15 日以现场投票和网络投票相结合的方式召开。 为确保公司股东充分了解本次股东大会的相关信息，现将相关事项提示公告如 下： 一、 召开会议的基本情况 (一) 股东会类型和届次 2025年第二次临时股东会 股东会召开日期：202 ...

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 广西柳药集团股份有限公司（以下简称"公司"）于 2025 年 8 月 28 日召开 第五届董事会第二十八次会议和第五届监事会第二十二次会议，分别审议通过了 《关于<广西柳药集团股份有限公司 2025 年股票期权激励计划（草案）及其摘要> 的议案》等相关议案。根据《上市公司股权激励管理办法》（以下简称"《管理办 法》"）等相关规定，公司对 2025 年股票期权激励计划（以下简称"本激励计划"） 激励对象的姓名和职务在公司内部进行了公示。公司董事会薪酬与考核委员会 （以下简称"薪酬委员会"）结合公示情况对激励对象名单进行了核查，相关公 示情况及核查情况如下： 一、公示情况及核查方式 1、公司对激励对象的内部公示情况 （1）公示内容：本激励计划激励对象的姓名及职务 （2）公示期间：2025 年 8 月 29 日至 2025 年 9 月 7 日（共计 10 日） | 证券代码：603368 | 证券简称：柳药集团 | 公告编号：2025-075 | | --- | --- | -- ...

Group 1 - The core point of the article is that Liu Pharmaceutical Group (603368.SH) has repurchased a total of 8.1079 million shares, which accounts for 2.04% of the company's total share capital as of September 8, 2025, indicating an increase of 0.76% compared to the previous announcement [1] - The highest price for the repurchased shares was 18.60 CNY per share, while the lowest price was 17.83 CNY per share [1] - The total amount paid for the repurchased shares was 148.4649 million CNY, excluding transaction fees [1]

Core Viewpoint - The company has repurchased a total of 8.1079 million shares, representing 2.04% of its total share capital, with an increase of 0.76% compared to the previous announcement [1] Summary by Relevant Sections - **Share Repurchase Details** - The highest price for the repurchased shares was 18.6 yuan per share, while the lowest price was 17.83 yuan per share [1] - The total amount paid for the repurchase was 148 million yuan, excluding transaction fees [1] - **Future Plans** - The expected amount for the repurchase is between 100 million yuan and 200 million yuan, intended for employee stock ownership plans or equity incentives [1]

Meeting Overview - The company is holding its second extraordinary general meeting of shareholders in 2025 on September 15 [2] - The meeting aims to ensure the normal order and efficiency of discussions while protecting the legal rights of all shareholders [3] Agenda Items - The meeting will discuss ten proposals, including five ordinary and five special resolutions [5] - Key proposals include the stock option incentive plan for 2025, employee stock ownership plan, and amendments to the company's articles of association [6][9] Stock Option Incentive Plan - The company has proposed a stock option incentive plan for 2025 to attract and retain talent, aligning the interests of shareholders, the company, and employees [10][11] - The plan includes a management assessment method to ensure its effective implementation [12] Employee Stock Ownership Plan - The company is also proposing an employee stock ownership plan for 2025 to enhance employee engagement and company competitiveness [17][18] - The plan aims to create a mechanism for shared risks and benefits among employees and shareholders [17] Governance Changes - The company plans to cancel its supervisory board, transferring its responsibilities to the audit committee of the board of directors [8] - Amendments to the company's articles of association will be made to reflect changes in governance structure and improve operational efficiency [8][9] Risk Management - The company intends to purchase liability insurance for directors and senior management to mitigate governance and operational risks [10]

Core Viewpoint - The company aims to enhance its operational efficiency and market share through digital transformation, AI integration, and strategic investments while navigating challenges in the pharmaceutical wholesale sector due to regulatory pressures and market dynamics [1][2][3]. Group 1: Company Performance - In the first half of 2025, the company reported a revenue of 10.301 billion yuan, a year-on-year decrease of 3.21%, and a net profit attributable to shareholders of 430 million yuan, down 7.52% compared to the previous year [1]. - The decline in performance is attributed to stricter control over drug expenditure by medical institutions and the impact of centralized procurement policies, leading to reduced sales and profit margins in the pharmaceutical wholesale business [1][6]. - The company is optimistic about gradually recovering growth through product structure optimization and the development of retail, industrial, and innovative business segments [1]. Group 2: AI and Digital Transformation - The company has implemented AI technologies in various areas, including supply chain management, hospital diagnostics, and retail health services, to enhance operational efficiency and customer engagement [2][3]. - AI applications include intelligent warehousing systems, patient management tools, and a digital health service model that integrates healthcare professionals to provide comprehensive patient care [2][3]. Group 3: Product Development and Market Expansion - The company is actively expanding its product lines in traditional Chinese medicine, with significant progress in the registration of traditional Chinese medicine granules and the establishment of partnerships with hospitals across multiple provinces [4]. - The company aims to increase the proportion of sales from traditional Chinese medicine granules outside its home province to 50% within 1 to 2 years [4]. Group 4: Financial Management and Cash Flow - The company has seen a year-on-year increase of 78.07% in net cash flow from operating activities, indicating improved cash management despite challenges in accounts receivable [5]. - The company is focusing on enhancing the quality of sales and improving cash flow by tightening control over accounts receivable and prioritizing high-quality customer relationships [5]. Group 5: Strategic Initiatives - The company has launched stock option and employee stock ownership plans to align employee interests with corporate goals, particularly focusing on the industrial sector's growth potential [8]. - The performance metrics for these plans emphasize net profit growth and the balance between operating cash flow and net profit, aiming to enhance operational safety and employee motivation [8].

Core Viewpoint - Liu Pharmaceutical Group reported a decline in revenue and net profit for the first half of 2025, primarily due to stricter control of drug usage ratios in medical institutions and the impact of centralized procurement policies [2] Financial Performance - For the first half of 2025, Liu Pharmaceutical Group achieved revenue of 10.301 billion yuan, a year-on-year decrease of 3.21% - The net profit attributable to shareholders was 430 million yuan, down 7.52% compared to the previous year [2] Business Challenges - The decline in performance is attributed to the significant impact of medical insurance cost control and the tightening of drug usage ratios in Guangxi's medical institutions, leading to a temporary decrease in medication volume [2] - The expansion of centralized procurement has also affected the gross margins of related products, while sales of non-centralized procurement products have been impacted [2] Strategic Initiatives - The company is focusing on optimizing its product structure, reducing costs, and enhancing efficiency, alongside the development of retail, industrial, and innovative businesses to gradually mitigate the impact of industry policies and restore stable growth [2] - Liu Pharmaceutical Group has implemented measures to control accounts receivable and improve cash flow, with a 78.07% increase in net cash flow from operating activities compared to the previous year [2][3] AI and Technology Integration - The company is leveraging AI technology in various areas, including the development of an intelligent warehouse system to optimize logistics operations and enhance supply chain efficiency [3][4] - AI applications are being integrated into hospital settings for patient management and diagnosis, with ongoing collaborations with hospitals to implement intelligent modules [4] - In the retail sector, Liu Pharmaceutical Group has introduced an AI pharmacist assistant to provide comprehensive health management services for patients [4][5] Innovation and R&D - Liu Pharmaceutical Group has invested in the overseas innovative drug company Suninflam Ltd., focusing on the development of monoclonal antibody drugs targeting key factors in inflammatory responses [5][6] - The project has successfully completed the efficacy evaluation and is currently in the process of conducting Phase I clinical trials for epilepsy in the United States, with promising preliminary results [6]

Core Viewpoint - Liu Pharmaceutical Group reported a decline in revenue and net profit for the first half of 2025, primarily due to stricter control on drug usage in public hospitals and the impact of centralized procurement policies [1][2] Financial Performance - For the first half of 2025, Liu Pharmaceutical Group achieved revenue of 10.301 billion yuan, a year-on-year decrease of 3.21% - The net profit attributable to shareholders was 430 million yuan, down 7.52% compared to the previous year [1] Business Challenges - The decline in performance is attributed to the significant impact of medical insurance cost control and stricter drug usage ratios in Guangxi's medical institutions - The company has also reduced sales to certain hospitals with long payment cycles, leading to decreased wholesale business sales and profit margins [1][2] Cash Flow and Receivables Management - The scale of accounts receivable decreased year-on-year, with a net cash flow from operating activities increasing by 78.07% compared to the same period last year - The company is focusing on improving cash flow by enhancing accounts receivable management and reducing risks associated with long payment cycles [2] AI and Technology Integration - Liu Pharmaceutical Group is implementing AI technologies in various areas, including supply chain management and hospital services - The company has developed an intelligent warehouse system and is applying AI algorithms to optimize logistics and operational efficiency [2][3] Healthcare Services Innovation - The company is launching AI-assisted services in hospitals, including intelligent triage and patient management - A dual-service model is being developed to provide comprehensive health management for outpatients, utilizing an AI pharmacist assistant [3] Investment in Innovation - Liu Pharmaceutical Group has invested in the overseas innovative drug company Suninflam Ltd., focusing on developing monoclonal antibody drugs targeting inflammation and neurodegenerative diseases - The first product, SIF001, has entered clinical trials in the U.S. and has shown promising efficacy in initial studies [4][5]